Shedding of membrane complement inhibitors CD59 and CD46 into the circulation is associated with poor prognosis in acute coronary syndrome patients: a cohort study

Table 4 Associations between CD46 and CD59 at 6 weeks and outcomes

Model	MACE (N = 30)			HF (N = 14)			Total mortality (N = 20)
Model	HR	CI	P	HR	CI	P	HR	CI	P
CD46
Model 1	0.88	0.58–1.34	0.547	0.82	0.44–1.52	0.525	0.99	0.61–1.60	0.955
Model 2	0.78	0.50–1.20	0.251	0.79	0.42–1.47	0.454	0.90	0.55–1.45	0.655
Model 3	0.79	0.50–1.26	0.326	0.69	0.34–1.40	0.303	0.79	0.44–1.40	0.418
CD59
Model 1	1.24	0.93–1.64	0.143	0.94	0.52–1.68	0.828	1.22	0.83–1.80	0.311
Model 2	1.10	0.80–1.52	0.548	0.86	0.45–1.61	0.629	1.02	0.64–1.62	0.944
Model 3	1.07	0.78–1.46	0.667	0.80	0.40–1.60	0.529	0.93	0.54–1.58	0.778

Adjustment models:
Model 1: unadjusted
Model 2: age and sex
Model 3: age, sex, CV risk factors (diabetes mellitus, hypertension, smoking), prevalent ACS, prevalent HF, revascularization (PCI/CABG)
ACS: acute coronary syndrome; MACE: major adverse cardiovascular event; HF: heart failure; HR: hazard ratio; CI: confidence interval

ISSN: 1479-5876